A Phase 3 interventional study of AIN457 (secukinumab) and Placebo in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 15th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 12th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2016, is one of 14 in phase 3, and was the 11th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in PsA patients with an inadequate response to non-biologic DMARDs. PDUS changes in joint synovitis will be assessed using the global Outcome Measures in Rheumatology (OMERACT)-European League against Rheumatism (EULAR) synovitis score (GLOESS) and changes in joint enthesitis were assessed using the OMERACT enthesitis score.
This was a 52-week, multicenter, international study consisting of a 2 to 4-week Screening period, a 12-week randomized, placebo-controlled double-blind treatment period (Period 1), a 12-week open-label treatment period (Period 2) and a 6-month open-label extension period (Period 3).
Treatment Period 1 is a 12-week placebo-controlled, randomized period primarily designed to demonstrate the early and optimal efficacy of secukinumab vs placebo on joint synovitis using PDUS via the GLOESS and global entheseal score after 12 weeks of treatment.
The main aim of Period 2 was to assess the maintenance or increased magnitude of treatment response on joint synovitis for patients from the original secukinumab groups and to assess the time course of response with secukinumab on joint synovitis in the original placebo group switched to secukinumab from Week 12.
The main aim of Period 3 (extension period) was to allow patients who respond to secukinumab to extend study treatment up to Week 52 or until commercial drug becomes available, whichever occurs sooner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Treatment Period-1: Patients in this group were administered secukinumab with 12 weeks of treatment from baseline. In Treatment Period-2: Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24 In Treatment Period 3 (extension period): the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52
Drug: AIN457 (secukinumab)
In Treatment Period-1: Patients received placebo at baseline and same time points as secukinumab until Week 8. In Treatment Period-2: Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12 In Treatment Period-3: Open-label secukinumab continued to be assigned to patients
Drug: AIN457 (secukinumab) · Drug: Placebo
Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis. Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.
Also known as: Secukinumab
Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)
Mixed model repeated measures (MMRM) analysis of change in Global OMERACT-EULAR Synovitis Score (GLOESS) score at Week 12 (observed data) to compare treatments The range for the GLOESS score is 0 to 144. GLOESS is the ultrasound scoring system measured for 24 pairs of joints. The scoring is from 0 to 3 for each joint; so the minimum score can be 0 and maximum can be 144.
Time frame: 12 weeks
Proportion of Participants With American College of Rheumatology (ACR)-20 Response
ACR 20 responder has ≥ 20% improvement in TJC and SJC and \>20% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's
Time frame: Week 12
Proportion of Participants With American College of Rheumatology (ACR)-50 Response
ACR 50 responder has ≥ 50% improvement in TJC and SJC and \>25% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of PsA pain, HAQ-DI, or hsCRP.
Time frame: Week 12
Spondyloarthritis Research Consortium of Canada (SPARCC)
Repeated measures mixed effect (MMRM) analysis of SPARCC total score change from baseline to Week 12 between the 2 treatment groups. SPARCC index ranges from 0 to 16.
Time frame: Baseline to Week 12
166 participants enrolled in 17 countries
| Milestone | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Started | 83 | 83 |
| Completed | 82 | 79 |
| Not completed | 1 | 4 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Started | 82 | 79 |
| Completed | 81 | 78 |
| Not completed | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Started | 81 | 78 |
| Completed | 75 | 69 |
| Not completed | 6 | 9 |
| Withdrew: Withdrew before entering period | 4 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Death | 0 | 1 |
Mixed model repeated measures (MMRM) analysis of change in Global OMERACT-EULAR Synovitis Score (GLOESS) score at Week 12 (observed data) to compare treatments The range for the GLOESS score is 0 to 144. GLOESS is the ultrasound scoring system measured for 24 pairs of joints. The scoring is from 0 to 3 for each joint; so the minimum score can be 0 and maximum can be 144.
| Adjusted Mean Change in scores | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS) | -9.05 ± 0.94 | -5.86 ± 0.93 |
ACR 20 responder has ≥ 20% improvement in TJC and SJC and \>20% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's
| Participants | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Proportion of Participants With American College of Rheumatology (ACR)-20 Response | 56 | 26 |
ACR 50 responder has ≥ 50% improvement in TJC and SJC and \>25% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of PsA pain, HAQ-DI, or hsCRP.
| Participants | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Proportion of Participants With American College of Rheumatology (ACR)-50 Response | 38 | 7 |
Repeated measures mixed effect (MMRM) analysis of SPARCC total score change from baseline to Week 12 between the 2 treatment groups. SPARCC index ranges from 0 to 16.
| Adjusted mean change in scores | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab |
|---|---|---|
| Spondyloarthritis Research Consortium of Canada (SPARCC) | -2.23 ± 0.29 | -1.57 ± 0.29 |
Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for 12 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group 1 - Secukinumab (150+300 mg) | 1/161 (0.6%) | 9/161 (5.6%) | 79/161 (49.1%) |
| Treatnent Group 2 - Placebo/Secukinumab | 0/83 (0%) | 2/83 (2.4%) | 27/83 (32.5%) |
| Event | Treatment Group 1 - Secukinumab (150+300 mg) | Treatnent Group 2 - Placebo/Secukinumab |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 2/161 | 0/83 |
| DiarrhoeaGastrointestinal disorders | 0/161 | 1/83 |
| Femur fractureInjury, poisoning and procedural complications | 0/161 | 1/83 |
| Atrial fibrillationCardiac disorders | 1/161 | 0/83 |
| Coronary artery stenosisCardiac disorders | 1/161 | 0/83 |
| COVID-19Infections and infestations | 1/161 | 0/83 |
| Incisional herniaInjury, poisoning and procedural complications | 1/161 | 0/83 |
| MalnutritionMetabolism and nutrition disorders | 1/161 | 0/83 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/161 | 0/83 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/161 | 0/83 |
| Event | Treatment Group 1 - Secukinumab (150+300 mg) | Treatnent Group 2 - Placebo/Secukinumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 19/161 | 4/83 |
| HeadacheNervous system disorders | 13/161 | 3/83 |
| DiarrhoeaGastrointestinal disorders | 7/161 | 6/83 |
| Urinary tract infectionInfections and infestations | 10/161 | 3/83 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/161 | 2/83 |
| HypertensionVascular disorders | 9/161 | 1/83 |
| BronchitisInfections and infestations | 8/161 | 2/83 |
| InfluenzaInfections and infestations | 7/161 | 3/83 |
| Dry eyeEye disorders | 3/161 | 3/83 |
| Abdominal painGastrointestinal disorders | 5/161 | 3/83 |
| Age, Categorical(Participants) | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab (150 mg + 300 mg) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 76 | 79 | 155 |
| >=65 years | 7 | 4 | 11 |
| Age, Continuous(years) | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab (150 mg + 300 mg) | Total |
|---|---|---|---|
| Mean | 46.7 ± 12.35 | 46.7 ± 12.08 | 46.7 ± 12.18 |
| Sex: Female, Male(Participants) | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab (150 mg + 300 mg) | Total |
|---|---|---|---|
| Female | 45 | 46 | 91 |
| Male | 38 | 37 | 75 |
| Race/Ethnicity, Customized(Participants) | Group 1 - Secukinumab (150 mg + 300 mg) | Group 2 - Placebo/Secukinumab (150 mg + 300 mg) | Total |
|---|---|---|---|
| Caucasian | 75 | 75 | 150 |
| Asian | 1 | 0 | 1 |
| Native American | 4 | 8 | 12 |
| Unknown | 2 | 0 | 2 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2016 to primary completion in Nov 2020, 50 months.
Results were first posted in Dec 2021, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 50 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab